Purpose: To describe an unusual manifestation of hyperreflective deposits in the subretinal space in a group of patients with clinically and genetically confirmed Stargardt disease.
R
ecessive Stargardt disease (STGD1) is the most common form of inherited, juvenile-onset retinal dystrophy affecting approximately 1 in 10,000 people worldwide. 1 Since its discovery as the causative gene for STGD1, over 1,000 mutations have been reported in the ATP-binding cassette, subfamily A member 4 (ABCA4) gene, 2 which produce a large spectrum of phenotypes ranging from bull's eye maculopathy 3, 4 to retina-wide degeneration. 5, 6 Despite such extensive clinical heterogeneity, ABCA4-associated diseases exhibit a well-defined profile of pathognomonic features that include the development and accumulation of yellow, pisciform-shaped foci (flecks) 7, 8 and sparing of the peripapillary region, 9 among others.
A more expanded profile includes characteristics associated with specific subgroups or progressive stages within the disease. For instance, retinal pigment epithelium (RPE) pigment migration 10 and choroidal sclerosis 11 are features associated with advanced disease stages, while external limiting membrane thickening 12 and fine, reflective dots in the central macula 13 have been described in younger patients. Documenting phenotypic spectrum of a disease increases diagnostic accuracy and provides insight into disease etiology.
Here, we describe an infrequent but discernible clinical manifestation of hyperreflective depositions in the macula and midperipheral retina in a group of patients diagnosed with advanced, genetically confirmed Stargardt disease.
Methods
All patients were enrolled under the protocol #AAAI9906 approved by the Columbia University Medical Center Institutional Review Board. All procedures adhered to the tenets set out in the Declaration of Helsinki. A retrospective review of clinical data from 296 genetically confirmed patients with Stargardt disease was performed. Patients included in the initial cohort underwent a complete ophthalmic examination by a retinal specialist (S.H.T.), including slit-lamp examination, dilated fundus examination, and measurement of best-corrected visual acuity. All patients were diagnosed with Stargardt disease and harbored at least two (as expected for a recessive disease) ABCA4 mutations detected by direct sequencing of all 50 exons and flanking intronic regions in the ABCA4 gene as previously described. 14, 15 Clinical data for all patients included color and red-free fundus photographs acquired by an FF 450plus Fundus Camera (Carl Zeiss Meditec AG, Jena, Germany), autofluorescence (AF) (488-nm excitation) images and spectral domain optical coherence tomography acquired with a Spectralis HRA + OCT module (Heidelberg Engineering, Heidelberg, Germany). In most, but not all patients, full-field electroretinogram (ffERG) results were available and included. Ganzfeld full-field electroretinograms (ERGs) for each patient were recorded using the Diagnosys Espion Electrophysiology System (Diagnosys LLC, Littleton, MA). Recordings were performed according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standards and guidelines. 16 
Results
A review of 296 clinically diagnosed and genetically confirmed patients with Stargardt disease revealed a small fraction of cases (n = 8, 2.7%) who presented with an unusual distribution of reflective yellow spots on fundoscopy and color fundus photographs ( Figure 1A) . The deposits were distributed in a nonspecific pattern across the macula and midperiphery but were discernibly more prevalent in the superotemporal region. The spots appeared to be largely round but varied in size from 50 mm to 70 mm. Distinct from yellow, pisciform flecks that represent lipofuscin accumulation and, therefore, produce an AF signal, these spots were only visible on reflective imaging modalities (color and red-free fundus photographs, near-infrared reflectance, and optical coherent tomography scans) and did not yield a detectable AF signal in the 488-nm range (short wavelength-autofluorescence) ( Figure 1B) . Furthermore, these deposits exhibit a hard, concrete appearance, which is different from the faint hue of the lipofuscin-derived flecks in the RPE. Correlations with these deposits in fundus images were found on spectral domain optical coherence tomography sections that revealed discrete, reflective granules of varying sizes in the subretinal space, specifically at the anterior side of the RPE layer (Figure 2 ). The granules were not visible in any other retinal layers.
Demographic, clinical, and genetic characteristics of the cohort are summarized in Table 1 . Mean age of the cohort is 38.7 years, ranging between 26 years and 57 years. No significant systemic history was noted with the exception of P3 who reported a history of hypertension. All except two patients reported visual symptoms within the first decade of life. Best-corrected visual acuities were predominantly poor in these patients, ranging from 20/300 to counting fingers, with the exception of P8 who presented with 20/100 and 20/ 30, right eye and left eye, respectively. Interestingly, all patients presented at relatively advanced stages of Stargardt disease. Features associated with "classical" Stargardt disease were observed in AF imaging ( Figure  1B) , including peripapillary sparing and heterogeneous patterns of flecks across the posterior pole. Full-field electroretinogram (ffERG) was analyzed in all patients except for P3 for whom data were not available. All cases exhibited generalized cone dysfunction, whereas P1, P3, P4, and P8 had also marginal to severe decreases in rod function.
In accordance with the advanced phenotypes, the ABCA4 genetic profile of the cohort consisted of deleterious variants across different classes of mutations, including a small deletion/frameshift variant, p. T1346Gfs*75, in P2 and several strong deleterious missense variants, p.P1380L and p.T1526M. As well as others including p.R2107H which is associated with African-American patients. 17 Two variants in canonical splice sites, c.6386+2C.G and c.4540-2A.G, were predicted to abolish splicing. The c.5461-10T.C variant found in P5 has been shown to cause exon skipping. 18 
Discussion
The progressive accumulation of numerous yellow flecks across the retina is a characteristic feature of Stargardt disease. The AF signal and subretinal localization of these flecks denote a connection to lipofuscin and in fact, it has been suggested that they represent lipofuscin-engorged RPE cells, displaced and stacked RPE, remnants of RPE cell lysis, or a byproduct of ongoing photoreceptor degeneration in the subretinal space. 7, 19, 20 The reflective deposits described in this cohort were similarly found in the subretinal space and yellow on fundoscopy and color fundus photographs, but differed in appearance and did not exhibit an AF signal. The deposits exhibit a round conformation and a rather solid appearance compared with the fluid and pyramidal-like appearance of flecks. Other forms of deposition in the macula of patients with Stargardt disease have been described. Fujinami et al 13 reported the observation of fine macula dots in a subset childhood onset cases; however, these dots are recognizably distinct from the deposition described in this study in that they are visible on AF and exhibit a different manifestation on OCT.
The actual composition of the reflective deposits is not known; however, because of its presence in patients with Stargardt disease, a connection to lipofuscin accumulation and ABCA4 pathology may exist. Furthermore, previous studies using quantitative AF have identified an increased presence of lipofuscin in the superotemporal region. 21 This is especially interesting, given the observation that the reflective deposits have a spatial preference for the superotemporal region as well. Deposition in this region may be a visual manifestation related to RPE damage based on previous observations that suggest a susceptibility of these cells in the superotemporal region. A vascular connection to the origin of these deposits may also be plausible as they bear an apparent resemblance to hard exudates found in vascular diseases. Histologic analyses have characterized the composition of these hard exudates as containing lipid-laden macrophages and other proteinaceous substances, which may be attributable to the etiology of lipofuscin in ABCA4 disease. [22] [23] [24] Contributions from the underlying vessels may also be possible as choroidal alterations have been reported in the course ABCA4 disease. 11, [25] [26] [27] Precise spatial correlations in the retina between the regions of deposition and choroidal thinning cannot be made; however, both were found to be evident features in the advanced stages of disease.
Several diseases have been associated with the retinal manifestation of crystalline deposition, ranging from genetic diseases related to enzyme deficiencies, including primary hyperoxalosis, 28 cystinosis, 29 hyperornithinemia, 30 Sjögren-Larsson syndrome, 31, 32 drug-induced retinopathies (tamoxifen, 33, 34 nitrofurantoin, 35 and talc 36, 37 ), primary ocular pathologies, such as Bietti crystalline retinopathy [38] [39] [40] or long-standing retinal detachments. 41 It is unlikely that the deposits are associated with a coexisting condition (including those listed above) in this cohort, given the negative medical history. They may rather represent an incidental complication associated with advanced disease stage. 42 This report expands the clinical spectrum of the ABCA4 disease, presenting an infrequent but notable prevalence of hyperreflective deposition in the subretinal space. The deposits are apparent in 2% to 3% of cases, localize at the superior region of the macula, and are found at an advanced disease stage. It is unclear whether these deposits are directly associated with the pathogenesis of ABCA4 dysfunction or are analogous to similar manifestations in other diseases, which affect the underlying choroidal or retinal vasculature.
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